Antiphospholipid Syndrome (APS) describes a systemic disease caused by autoantibodies to membrane components. Involving coagulation pathways, complement factors and immune cells, it results in thrombosis in any blood vessel. Its clinical presentation varies considerably depending upon the organ affected. Paediatric data on APS remain sparse. Most case reports focus on catastrophic APS with multiple smallvessel occlusions and a life-threatening course. Here, we report on a 15-year-old patient with deep vein thrombosis and a right ventricular tumour posing the risk of a fulminant pulmonary embolism. The tumour was surgically removed. Histology revealed it to be a thrombus. The patient fully recovered and is currently treated with long term anticoagulation. Case report ▼ A previously healthy 15-year-old male was referred to our institution presenting with deep vein thrombosis (DVT) in the right Vena poplitea and the distal Vena femoralis after first having suffered intense pain in the right popliteal fossa and then experiencing an 18-hour-long episode of immobility. Prior to this episode, he had felt intermittent pain in his right calf over a 2-month period without evidence of a traumatic origin. The patient's history was negative for other diseases and allergies; he was of normal weight (BMI 19.6 Table 1 ). After administration of low molecular weight heparin (LMWH) at a therapeutic level of 0.6-0.8 IE/ml, the patient was discharged. Occurrence of an unprovoked DVT, aPTT prolongation and thrombocytopenia with only merely elevated d-dimers was highly suspicious for APS, therefore aPL were investigated as well. However, results were not available prior to discharge. 6 days later, the patient returned to the hospital for a non-irradiating right-sided chest pain. The aPL test revealed high titres for LA, phospholipid β2 glycoprotein I IgM and phospholipid β2 glycoprotein I IgG antibodies ( • ▶ Table 2 ).
Zusammenfassung
Antinuclear antibodies were also positive (HEp-2 nucleoles 1:50, homogenous pattern), while complement factor C3 and C4 were normal (C3 0.96 g/l; 0.90-1.80 g/l, C4 0.17 g/l; 0.10-0.40 g/l). An ECG showed no anomaly, nor did chest radiography. Echocardiography revealed an intracardiac mass -a floating, tumorous structure 14 × 15 mm in size. This was located in the right ventricle and attached to the septomarginal trabecula and chordae tendineae of the tricuspid valve ( • ▶ Fig. 1 ). Ventricular wall contraction was not affected, nor was tricuspid and pulmonary blood flow. However, his left ventricular ejection fraction was reduced to 39 %, most likely due to interventricular septum bulging into the left ventricle. For the purpose of excluding a rhabdomyoma, our patient underwent a cardio-MRI, which confirmed the location of the mass, yet displayed equivalent signalling to the myocardium ( • ▶ Fig. 2 ). Due to the impending risk of fulminant embolisation in the main pulmonary artery, we chose not to initiate lysis; instead, we had the mass excised via median sternotomy and cardiopulmonary bypass surgery. Intraoperatively, we observed a hard, calcified mass attached to the subvalvular apparatus of the tricuspid valve. After excision, the tricuspid valve needed to be reconstructed by transposing the papillary muscle. Histopathological examination revealed an encapsulated, calcified thrombotic structure. After having ruled out hereditary thrombophilia, we diagnosed APS, as it is associated with high titres of LA and phospholipid β2 glycoprotein I antibodies. Postoperative echocardiographies displayed a good morphological and functional outcome ( • ▶ Fig. 3 ). Recurrent phlebography of the lower extremities revealed that the DVT had resolved. However, aPL values remained pathologically elevated ( • ▶ Table 2 ). Additional laboratory (haemoglobin, leuco- cytes, lymphocytes, Coombs test, extractable nuclear antigen and dsDNA antibodies) as well as clinical SLE parameters has been negative to date. The patient is continuing to take coumarin derivatives for long-term anticoagulation.
Discussion ▼
Here, we report on a rare manifestation of APS in conjunction with the development of a life-threatening intracardiac thrombus in an adolescent who lacks any inherited risk factors for thrombosis. The encapsulated, calcified clot suggests a long evolution of this cardiac embolus, one that likely originated from the previously diagnosed DVT in his right leg. Phospholipid β2 glycoprotein I IgG antibodies were notably increased, while IgM titres were only slightly elevated. Thus, both clinical and laboratory criteria for an APS pointed to long-lasting autoimmuneinduced clot formation. The pathogenesis of APS often has been described by a "two-hit" hypothesis. After an initial injury to the endothelial wall, a second "hit" such as pregnancy, infection, smoking, hypertension, atherosclerosis, obesity, vascular stasis, trauma or surgery triggers the development of thrombosis (Giordano P. et al., Blood Transfus 2012; 6; 296-301). Our patient had none of these risk factors. The preceding episode of 18-hourlong immobility represents the only potential trigger for additional clot formation. Yet, the uncertainty of the time course of DVT and cardiac thrombus resulted in an uncertainty of transient triggers. Thrombocytopenia is included in the so-called non-criteria manifestation of APS (Aguiar C. L. et al., Curr Rheumatol Rep 2015; 1; 27). Moreover, LA is an important cause of aPTT prolongation in children (Male C. et al., J Pediatr 1999; 7; 199-205) . Even though LA is transient in most children, both these findings pointed to an autoimmune process in our patient that proved to be true. This observation underlines the importance of APS screening in all paediatric patients with unprovoked thrombosis, particularly in adolescents (Male C. et al., J Pediatr 1999; 7; 199-205) . APS is subdivided in a primary and a secondary form. While conditions leading to the onset of primary APS remain unknown, SLE represents the most important underlying disease in 83 % of secondary APS (Aguiar C. L. et al., Curr Rheumatol Rep 2015; 1; 27) . Indeed, our patient tested positive for ANA and presented from the onset of his disease thrombocytopenia with only slightly elevated d-dimers. Yet, no additional clinical or laboratory SLE characteristics have been detected on follow-up for 10 months. Interestingly, patients with secondary APS tend to test positive for more than one aPL class. This was also the case with our patient. Furthermore, positive aPL in SLE patients increases the risk of venous thrombosis by up to a factor of 6 (Weiss J. E., Pediatr Rev 2012; 11; 62-73; quiz 74). Because our patient so far has not formally met the SLE criteria, our current working assumption is that he has primary APS. Nevertheless, close follow-up for SLE will be performed, since progression of primary APS to SLE is known to occur in up to 30 % of paediatric patients. Screening in our patient did not impact on acute treatment, yet resulted in long-term therapy with coumarins according to the current recommendations (Erkan D. et al., Autoimmun Rev 2014; 3; 685-696) . The recommended targeted INR remains controversial (Espinosa G. et al., Ann Rheum Dis 2002; 5; 195-198) . In our case, targeted INR is 3.0-3.5. Low-dose ASS in asymptomatic positive aPL did not convey any benefit, yet might even increase the risk of bleeding. ASS may be indicated in APS patients with underlying SLE that bare a 50 % risk of thrombosis within 10 years (Aguiar C. L. et al., Curr Rheumatol Rep 2015; 1; 27) , as well as in aPL-positive patients with thrombocytopenia (Espinosa G. et al., Nat Rev Rheumatol 2015; 4; 586-596) . The 2014 report of the APS Treatment Trends Task Force lists several treatment options (Erkan D. et al., Autoimmun Rev 2014; 3; 685-696) : the use of oral anticoagulants and statins is recommended only for subgroups with insufficient anticoagulation under coumarin. B-cell and complement inhibition may serve for APS patients refractory to anticoagulation. The role of hydroxychloroquine in primary thrombosis prevention remains to be elucidated. Hence, for SLE patients, hydroxychloroquine is generally recommended as an adjunctive treatment (Espinosa G. and R. Cervera, Nat Rev Rheumatol 2015; 4; 586-596).
The distribution of arterial and venous thrombosis undergoes changes with age. While more than half of thrombosis cases in infants are arterial in origin, this ratio decreases in paediatric patients among whom DVT constitutes the main manifestation. Pulmonary embolism represents the most common manifestation of pulmonary APS and accounts for 9 % of cases in adult APS (Espinosa G. et al., Ann Rheum Dis 2002; 5; 195-198) . It may even be the first manifestation of APS. Despite the lower risk of pulmonary embolism in children with APS (Ravelli A. et al., Rheum Dis Clin North Am 1997; 8; 657-676) , we continue to recommend that paediatricians be aware of this complication when diagnosing DVT or other clot manifestations.
Conclusion ▼
This case describes a paediatric patient who presented with an intracardiac thrombus as part of an early manifestation of primary APS. We suggest testing for aPL in all paediatric patients presenting with clot formation, thrombocytopenia and prolonged aPTT. Echocardiography should be performed as a screening method for intracardiac thrombosis in these patients.
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